Journal Mobile Options
Table of Contents
Vol. 27, No. 4, 2009
Issue release date: November 2009
Section title: Pathogenesis of IBD
Free Access
Dig Dis 2009;27:455–464

Inflammation in the Intestinal Tract: Pathogenesis and Treatment

Blumberg R.S.
Gastroenterology Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass., USA
email Corresponding Author

Richard S. Blumberg, MD

Gastroenterology Division, Brigham and Women’s Hospital

Harvard Medical School, 75 Francis Street, Thorn Research Building, Rm 1419

Boston, MA 02115 (USA)

Tel. +1 617 732 6917, Fax +1 617 264 5185, E-Mail


  1. Kaser A, et al: XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008;134:743–756.
  2. Hanauer SB, et al: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323–333.
  3. Ito H, et al: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 2004;126:989–996.
  4. Present DH, et al: Inflimximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–1405.
  5. Sandborn WJ, et al: Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357:228–238.
  6. Targan SR, et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 1997;337:1029–1035.
  7. Mannon PJ, et al: Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med 2004;351:2069–2079.
  8. Hommes DW, et al: Fontulizumab, a humanized anti-interferon-γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease. Gut 2006;55:1131–1137.